Source: Oral diseases. Unidade: FM
Subjects: CARCINOMA DE CÉLULAS ESCAMOSAS, QUIMIOTERÁPICOS, INIBIDORES DE ENZIMAS
ABNT
ALMEIDA, Luciana Yamamoto de et al. FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1. Oral diseases, v. 29, n. 2, p. 649-660, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/52816. Acesso em: 21 maio 2024.APA
Almeida, L. Y. de, Moreira, F. D. S., Santos, G. A. S. D., Zelaya, F. J. M. C., Ortiz, C. A., Agostini, M., et al. (2023). FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1. Oral diseases, 29( 2), 649-660. doi:10.1111/odi.14017NLM
Almeida LY de, Moreira FDS, Santos GASD, Zelaya FJMC, Ortiz CA, Agostini M, Mariano FS, Bastos DC, Daher URN, Kowalski LP. FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1 [Internet]. Oral diseases. 2023 ; 29( 2): 649-660.[citado 2024 maio 21 ] Available from: https://observatorio.fm.usp.br/handle/OPI/52816Vancouver
Almeida LY de, Moreira FDS, Santos GASD, Zelaya FJMC, Ortiz CA, Agostini M, Mariano FS, Bastos DC, Daher URN, Kowalski LP. FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1 [Internet]. Oral diseases. 2023 ; 29( 2): 649-660.[citado 2024 maio 21 ] Available from: https://observatorio.fm.usp.br/handle/OPI/52816